Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolio
Close

Innopharmax (4172)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
15.35 +0.15    +0.99%
09/05 - Closed. Currency in TWD ( Disclaimer )
  • Volume: 141,072
  • Bid/Ask: 8.43 / 8.84
  • Day's Range: 15.05 - 15.60
Type:  Equity
Market:  Taiwan
ISIN:  TW0004172002 
Innopharmax 15.35 +0.15 +0.99%

Innopharmax Company Profile

 
Read the Innopharmax company profile to learn more about the business and the management team. View Innopharmax facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

33

Equity Type

ORD

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company’s core products include N11005, a prandial oral insulin; and GemOral. It also offers Imipenem and Cilastatin solution for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents consisting of gadopentetate dimeglumine and gadodiamide; oncology agents comprising Innomustine and Immurin; and Inpheno tablets for rare diseases. In addition, the company provides MUCR system, OralPas, and OralPas Pro technology platform. Its product pipeline comprises D07001, which is in phase I trial for treatment of tumor; C08001, which is in phase lll for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction; D07002, which is in pilot BE trial used as a supplement for phenylketonuria; and C07001, which is in pilot BE trial for the treatment of parkinson’s disease; N11001, which is in pilot BE as urology agents; and D0131502 and D0051301 as contrast agents and is in formulation. The company was founded in 1994 and is based in Taipei, Taiwan.

Contact Information

Address No. 20 and No. 22, Lane 478 9th Floor
Ruiguang Road Neihu District Taipei, 11492
Taiwan
Phone 886 2 8797 7607
Fax 886 2 8797 5627
Web www.innopharmax.com
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

4172 Price Commentary

Write your thoughts about Innopharmax
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email